期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 7, 期 1, 页码 34-39出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.5b00302
关键词
Class IIa HDAC inhibitors; hydroxamic acid; CNS exposure; tetrasubstituted cyclopropane; cyclopropanation; Huntington's disease
Potent and selective class Ha HDAC tetrasubstituted cyclopropane hydroxamic acid inhibitors were identified with high oral bioavailability that exhibited good brain and muscle exposure. Compound 14 displayed suitable properties for assessment of the impact of class Ha HDAC catalytic site inhibition in preclinical disease models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据